Treatment of liposclerosis of the leg by fibrinolytic enhancement: a preliminary report.

Abstract

Fourteen patients with longstanding lipodermatosclerosis of their lower legs, secondary to venous disease in 11, were treated for three months with stanozolol, a drug that enhances fibrinolytic activity. No other treatment was given and no change made in existing treatment. All the patients improved. Two were cured in three months, three were able to stop treatment in the next three to 11 months, and the other nine continued to improve. Fibrinolytic enhancement, with stanozolol, seems to be a worthwhile addition to the treatment of venous liposclerosis and deserves further study.

• Authors: N L Browse, P E Jarrett, M Morland, K Burnand
• Journal: British medical journal (Br Med J) Vol. 2 Issue 6084 Pg. 434-5 (Aug 13 1977) ISSN: 0007-1447 [Print] England
• PMID: 890326 (Publication Type: Journal Article)

Chemical References

• Stanozolol

Topics

• Adult
• Female
• Humans
• Leg Dermatoses (drug therapy, etiology)
• Male
• Middle Aged
• Sclerosis (drug therapy, etiology)
• Stanozolol (therapeutic use)
• Vascular Diseases (complications)